{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eltrombopag+olamine", "query": { "intervention": "eltrombopag olamine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eltrombopag+olamine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T04:08:05.527Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01772420", "title": "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Myelodysplastic Syndrome", "Anemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Eltrombopag Olamine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2012-10", "completion_date": "2020-07-09", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 2, "location_summary": "Kansas City, Kansas • The Bronx, New York", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772420" }, { "nct_id": "NCT00351468", "title": "EXTEND (Eltrombopag Extended Dosing Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "eltrombopag olamine (SB-497115-GR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2006-06", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00351468" }, { "nct_id": "NCT00643929", "title": "LENS - Long-term Eltrombopag Observational Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 164, "start_date": "2007-02", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 5, "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643929" }, { "nct_id": "NCT00903422", "title": "Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2009-05-14", "completion_date": "2013-12-05", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903422" }, { "nct_id": "NCT01428635", "title": "Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Primary Myelofibrosis", "Thrombocytopenia" ], "interventions": [ { "name": "Eltrombopag Olamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-01-13", "completion_date": "2022-01-03", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01428635" }, { "nct_id": "NCT01927731", "title": "Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Marrow Transplantation Recipient", "Cord Blood Transplant Recipient", "Hematopoietic Cell Transplantation Recipient" ], "interventions": [ { "name": "Eltrombopag Olamine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-10-14", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01927731" }, { "nct_id": "NCT01098487", "title": "A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "Eltrombopag olamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2010-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-03-12", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098487" }, { "nct_id": "NCT01550185", "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Buffalo, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01550185" }, { "nct_id": "NCT01147809", "title": "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombocytopaenia" ], "interventions": [ { "name": "Eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2010-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 33, "location_summary": "Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147809" }, { "nct_id": "NCT00370331", "title": "RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2006-11", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-12T04:08:05.527Z", "location_count": 26, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00370331" } ] }